Food and Drug Amendments of 2022

Summary

Food and Drug Amendments of 2022 This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices. Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars. The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials. In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

11 official files

• Received in Senate (text)

  Received in Senate · EN · 9 June 2022

  ViewDownloadOpen at official source

• Received in Senate (PDF)

  Received in Senate · EN · 9 June 2022

  ViewDownloadOpen at official source

• Engrossed in House (text)

  Engrossed in House · EN · 8 June 2022

  ViewDownloadOpen at official source

• Engrossed in House (PDF)

  Engrossed in House · EN · 8 June 2022

  ViewDownloadOpen at official source

• Passed House

  summary · EN · 8 June 2022

  Open at official source

• Reported in House (text)

  Reported in House · EN · 7 June 2022

  ViewDownloadOpen at official source

• Reported in House (PDF)

  Reported in House · EN · 7 June 2022

  ViewDownloadOpen at official source

• Reported to House

  summary · EN · 7 June 2022

  Open at official source

• Introduced in House (text)

  Introduced in House · EN · 6 May 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 6 May 2022

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 6 May 2022

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.